Please login to the form below

Not currently logged in
Email:
Password:

sirukumab

This page shows the latest sirukumab news and features for those working in and with pharma, biotech and healthcare.

GSK sells eczema and psoriasis drug to Dermavant for £250m

GSK sells eczema and psoriasis drug to Dermavant for £250m

The cut included IL-6 inhibitor sirukumab for rheumatoid arthritis, which left tapinarof as the lead candidate in its immuno-inflammation programme.

Latest news

More from news
Approximately 7 fully matching, plus 16 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics